SLE
MCID: LPS004
MIFTS: 64

Lupus Erythematosus (SLE) malady

Categories: Rare diseases, Skin diseases, Immune diseases, Genetic diseases, Nephrological diseases, Bone diseases

Aliases & Classifications for Lupus Erythematosus

Aliases & Descriptions for Lupus Erythematosus:

Name: Lupus Erythematosus 12 50 52 14 69
Lupus 12 50 41 3 14
Subacute Cutaneous Lupus 50 69
Disseminated Lupus Erythematosus 50
Lupus Erythematosus, Systemic 69
Systemic Lupus Erythematosus 50
Lupus Erythematosus, Discoid 69
Lupus Vulgaris 69
Discoid Lupus 50
Sle 50

Classifications:



External Ids:

Disease Ontology 12 DOID:8857
ICD10 33 L93 L93.0
ICD9CM 35 695.4
NCIt 47 C27153
SNOMED-CT 64 200936003 200944003
UMLS 69 C0409974

Summaries for Lupus Erythematosus

MedlinePlus : 41 what is lupus? lupus is an autoimmune disease. this means that your immune system attacks healthy cells and tissues by mistake. this can damage many parts of the body, including the joints, skin, kidneys, heart, lungs, blood vessels, and brain. there are several kinds of lupus systemic lupus erythematosus (sle) is the most common type. it can be mild or severe, and can affect many parts of the body. discoid lupus causes a red rash that doesn't go away subacute cutaneous lupus causes sores after being out in the sun drug-induced lupus is caused by certain medicines. it usually goes away when you stop taking the medicine. neonatal lupus, which is rare, affects newborns. it is probably caused by certain antibodies from the mother. who gets lupus? anyone can get lupus, but women are most at risk. lupus is two to three times more common in african american women than in caucasian women. it's also more common in hispanic, asian, and native american women. african american and hispanic women are more likely to have severe forms of lupus. what causes lupus? the cause of lupus is not known. what are the symptoms of lupus? lupus can have many symptoms, and they differ from person to person. some of the more common ones are pain or swelling in joints muscle pain fever with no known cause red rashes, most often on the face (also called the "butterfly rash") chest pain when taking a deep breath hair loss pale or purple fingers or toes sensitivity to the sun swelling in legs or around eyes mouth ulcers swollen glands feeling very tired symptoms may come and go. when you are having symptoms, it is called a flare. flares can range from mild to severe. new symptoms may appear at any time. how do i know if i have lupus? there is no single test to diagnose lupus, and it's often mistaken for other diseases. so it may take months or years for a doctor to diagnose it. your doctor may use many tools to make a diagnosis: medical history complete exam blood tests skin biopsy (looking at skin samples under a microscope) kidney biopsy (looking at tissue from your kidney under a microscope) what are the treatments for lupus? there is no cure for lupus, but medicines and lifestyle changes can help control it. people with lupus often need to see different doctors. you will have a primary care doctor and a rheumatologist (a doctor who specializes in the diseases of joints and muscles). which other specialists you see depends on how lupus affects your body. for example, if lupus damages your heart or blood vessels, you would see a cardiologist. your primary care doctor should coordinate care between your different health care providers and treat other problems as they come up. your doctor will develop a treatment plan to fit your needs. you and your doctor should review the plan often to be sure it is working. you should report new symptoms to your doctor right away so that your treatment plan can be changed if needed. the goals of the treatment plan are to prevent flares treat flares when they occur reduce organ damage and other problems treatments may include drugs to reduce swelling and pain prevent or reduce flares help the immune system reduce or prevent damage to joints balance the hormones besides taking medicines for lupus, you may need to take medicines for problems that are related to lupus such as high cholesterol, high blood pressure, or infection. alternative treatments are those that are not part of standard treatment. at this time, no research shows that alternative medicine can treat lupus. some alternative or complementary approaches may help you cope or reduce some of the stress associated with living with a chronic illness. you should talk to your doctor before trying any alternative treatments. how can i cope with lupus? it is important to take an active role in your treatment. it helps to learn more about lupus - being able to spot the warning signs of a flare can help you prevent the flare or make the symptoms less severe. it is also important to find ways to cope with the stress of having lupus. exercising and finding ways to relax may make it easier for you to cope. a good support system can also help. nih: national institute of arthritis and musculoskeletal and skin diseases

MalaCards based summary : Lupus Erythematosus, also known as lupus, is related to c1q deficiency and membranoproliferative glomerulonephritis, and has symptoms including cyanosis, exanthema and icterus. An important gene associated with Lupus Erythematosus is TLR5 (Toll Like Receptor 5), and among its related pathways/superpathways are Innate Immune System and Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3. The drugs Simvastatin and Tacrolimus have been mentioned in the context of this disorder. Affiliated tissues include t cells, skin and b cells, and related phenotypes are hematopoietic system and immune system

NIH Rare Diseases : 50 lupus is an autoimmune disease that can affect almost every organ in the body. symptoms of lupus can range from very mild to life-threatening. there are three types of lupus; systemic lupus erythematosus, discoid lupus, and drug-induced lupus. genetics is thought to play a role in the development of lupus along with other lifestyle and environmental factors. studies suggest that a number of different genes may be involved in determining a person’s likelihood of developing the disease, which tissues and organs are affected, and the severity of disease. the treatment of lupus depends on the severity of the condition and what parts of the body are affected. treatment may include acetaminophen, ibuprofen, antimalarial drugs, anti-inflammatory steroids, and/or immunosuppressive drugs. last updated: 8/26/2015

CDC : 3 Lupus occurs when an unknown trigger causes a person’s own immune system to attack their tissues, damaging the tissues and producing widespread inflammation. There is no known cause or cure for lupus; however, treatments are available.

Wikipedia : 71 Lupus erythematosus is a name given to a collection of autoimmune diseases in which the human immune... more...

Related Diseases for Lupus Erythematosus

Diseases in the Lupus Erythematosus family:

Systemic Lupus Erythematosus Systemic Lupus Erythematosus 14
Systemic Lupus Erythematosus 9 Systemic Lupus Erythematosus 1
Systemic Lupus Erythematosus 11 Systemic Lupus Erythematosus 2
Systemic Lupus Erythematosus 16 Systemic Lupus Erythematosus 3
Systemic Lupus Erythematosus 13 Systemic Lupus Erythematosus 10
Systemic Lupus Erythematosus 12 Systemic Lupus Erythematosus 4
Systemic Lupus Erythematosus 5 Systemic Lupus Erythematosus 7
Systemic Lupus Erythematosus 8 Cr2-Related Susceptibility to Systemic Lupus Erythematosus
Dnase1-Related Susceptibility to Systemic Lupus Erythematosus Itgam-Related Susceptibility to Systemic Lupus Erythematosus

Diseases related to Lupus Erythematosus via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 832)
id Related Disease Score Top Affiliating Genes
1 c1q deficiency 32.7 C1QA C1QB C1QC
2 membranoproliferative glomerulonephritis 29.8 CD40LG TRIM21 XRCC6
3 systemic lupus erythematosus 12.8
4 lupus erythematosus tumidus 12.6
5 subacute cutaneous lupus erythematosus 12.5
6 lupus erythematosus panniculitis 12.5
7 discoid lupus erythematosus 12.5
8 systemic lupus erythematosus 16 12.5
9 neonatal lupus erythematosus 12.5
10 cutaneous lupus erythematosus 12.4
11 drug-induced lupus erythematosus 12.4
12 systemic lupus erythematosus 1 12.4
13 systemic lupus erythematosus 2 12.3
14 systemic lupus erythematosus 9 12.2
15 systemic lupus erythematosus 10 12.2
16 pediatric systemic lupus erythematosus 12.2
17 systemic lupus erythematosus 11 12.2
18 chilblain lupus 12.2
19 systemic lupus erythematosus 3 12.1
20 systemic lupus erythematosus 12 12.1
21 systemic lupus erythematosus 4 12.1
22 hypertrophic or verrucous lupus erythematosus 12.1
23 neonatal systemic lupus erythematosus 12.0
24 systemic lupus erythematosus 14 12.0
25 systemic lupus erythematosus with nephritis 2 12.0
26 systemic lupus erythematosus 13 12.0
27 systemic lupus erythematosus with nephritis 1 12.0
28 systemic lupus erythematosus with nephritis 3 12.0
29 systemic lupus erythematosus 5 12.0
30 systemic lupus erythematosus 7 12.0
31 systemic lupus erythematosus 8 12.0
32 discoid lupus erythematosus of eyelid 11.9
33 cr2-related susceptibility to systemic lupus erythematosus 11.9
34 dnase1-related susceptibility to systemic lupus erythematosus 11.9
35 itgam-related susceptibility to systemic lupus erythematosus 11.9
36 systemic lupus erythematous, association with 6 11.6
37 vitiligo-associated multiple autoimmune disease susceptibility 1 11.6
38 mixed connective tissue disease 11.4
39 pure red-cell aplasia 11.3
40 sjogren's syndrome 11.3
41 epidermolysis bullosa acquisita 11.3
42 collagen disease 11.3
43 retinal vasculitis 11.3
44 pemphigus erythematosus 11.3
45 macrophage activation syndrome 11.3
46 c2 deficiency 11.3
47 undifferentiated connective tissue disease 11.2
48 c3 deficiency 11.2
49 sneddon syndrome 11.2
50 c1s deficiency 11.2

Graphical network of the top 20 diseases related to Lupus Erythematosus:



Diseases related to Lupus Erythematosus

Symptoms & Phenotypes for Lupus Erythematosus

UMLS symptoms related to Lupus Erythematosus:


cyanosis, exanthema, icterus, pruritus, lupus-like rash, seizures

MGI Mouse Phenotypes related to Lupus Erythematosus:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.85 C3 C4B CD40LG CTLA4 PTPN22 SSB
2 immune system MP:0005387 9.7 SSB TLR5 TRIM21 TROVE2 XRCC6 C1QA
3 renal/urinary system MP:0005367 9.17 C1QA C3 C4B CD40LG PTPN22 TRIM21

Drugs & Therapeutics for Lupus Erythematosus

Drugs for Lupus Erythematosus (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 355)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Simvastatin Approved Phase 4,Phase 1,Early Phase 1 79902-63-9 54454
2
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 104987-11-3 445643 439492
3
Cyclophosphamide Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 50-18-0, 6055-19-2 2907
4
Mycophenolic acid Approved Phase 4,Phase 3,Phase 2,Phase 1 24280-93-1 446541
5
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 128794-94-5 5281078
6
Hydroxychloroquine Approved Phase 4,Phase 3,Phase 1,Phase 2 118-42-3 3652
7
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-24-8 5755
8
Benzocaine Approved Phase 4,Phase 3,Phase 1 1994-09-7, 94-09-7 2337
9
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 83-43-2 6741
10
Prednisone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 53-03-2 5865
11
Pioglitazone Approved, Investigational Phase 4,Phase 1,Phase 2 111025-46-8 4829
12
Aspirin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-78-2 2244
13
Azathioprine Approved Phase 4,Phase 3,Phase 2,Phase 1 446-86-6 2265
14
Triamcinolone Approved, Vet_approved Phase 4,Phase 2,Phase 1 124-94-7 31307
15
belimumab Approved Phase 4,Phase 3,Phase 2,Phase 1 356547-88-1 5957 10451420
16
Metformin Approved Phase 4 657-24-9 14219 4091
17
Bortezomib Approved, Investigational Phase 4,Phase 2 179324-69-7 387447 93860
18
Sulfamethoxazole Approved Phase 4 723-46-6 5329
19
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
20
Calcitriol Approved, Nutraceutical Phase 4,Phase 2 32222-06-3 134070 5280453
21 tannic acid Approved, Nutraceutical Phase 4,Phase 3,Phase 1
22
leucovorin Approved, Nutraceutical Phase 4,Phase 3,Phase 2 58-05-9 54575, 6560146 143
23
Alfacalcidol Approved, Nutraceutical Phase 4 41294-56-8 5282181
24
Ergocalciferol Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1 50-14-6 5280793
25
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 59-30-3 6037
26 Prednisolone acetate Phase 4,Phase 3,Phase 2,Phase 1
27 Atorvastatin Calcium Phase 4,Phase 2,Phase 3,Phase 1 134523-03-8
28 Rosuvastatin Calcium Phase 4,Phase 2,Phase 1 147098-20-2
29 Analgesics Phase 4,Phase 2,Phase 3,Phase 1
30 Alkylating Agents Phase 4,Phase 2,Phase 3,Phase 1
31 glucocorticoids Phase 4,Phase 3,Phase 2,Phase 1
32 Gastrointestinal Agents Phase 4,Phase 2,Phase 3,Phase 1
33 Neuroprotective Agents Phase 4,Phase 3,Phase 2,Phase 1
34 Analgesics, Non-Narcotic Phase 4,Phase 2,Phase 3,Phase 1
35 Trace Elements Phase 4,Phase 3,Phase 2,Phase 1
36 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
37 Hormones Phase 4,Phase 3,Phase 2,Phase 1
38 Vaccines Phase 4,Phase 2,Phase 3,Phase 1
39 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3,Phase 1
40 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
41 Vasoconstrictor Agents Phase 4,Phase 2
42 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
43 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1
44 Vitamins Phase 4,Phase 3,Phase 2,Phase 1
45 Estrogens Phase 4,Phase 3,Phase 2
46 Hypolipidemic Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
47 Immunoglobulins Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
48 Prednisolone hemisuccinate Phase 4,Phase 3,Phase 2,Phase 1
49 Prednisolone phosphate Phase 4,Phase 3,Phase 2,Phase 1
50 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 612)
id Name Status NCT ID Phase
1 Study of Endothelial Dysfunction in Systemic Lupus and Its Role in Heart Disease Unknown status NCT00188188 Phase 4
2 Efficacy and Adverse Effect of Simvastatin Compare to Rosuvastatin in Systemic Lupus Erythematosus (SLE) Patients With Corticosteroid Therapy and High Low-Density Lipoprotein (LDL) Cholesterol Level Unknown status NCT00866229 Phase 4
3 Immune Response After Human Papillomavirus Vaccination in Patients With Autoimmune Disease Unknown status NCT00815282 Phase 4
4 Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases Unknown status NCT01151644 Phase 4
5 A Study to Evaluate the Effect of Belimumab on Vaccine Responses in Subjects With Systemic Lupus Erythematosus (SLE) Completed NCT01597492 Phase 4
6 The Reduction of Systemic Lupus Erythematosus Flares :Study PLUS Completed NCT00413361 Phase 4
7 Effect of Pioglitazone on Endothelial Function in Premenopausal Women With Uncomplicated Systemic Lupus Erythematosus Completed NCT01322308 Phase 4
8 Open-label Trial of Acthar Gel in Subjects With Moderate to Severe Active Systemic Lupus Erythematosus Completed NCT01769937 Phase 4
9 Steroid Induced Osteoporosis in Patients With Systemic Lupus Erythematosus Completed NCT00668330 Phase 4
10 Tacrolimus for the Treatment of Systemic Lupus Erythematosus With Membranous Nephritis Completed NCT00125307 Phase 4
11 Aspirin and Statins for Prevention of Atherosclerosis and Arterial Thromboembolism in Systemic Lupus Erythematosus Completed NCT00371501 Phase 4
12 Mycophenolate Mofetil in Systemic Lupus Erythematosus (MISSILE) Completed NCT01101802 Phase 4
13 Effect of Hormone Replacement Therapy on Lupus Activity Completed NCT00392093 Phase 4
14 Immunogenicity and Safety of a Quadrivalent Human Papillomavirus (HPV) Vaccine in Patients With SLE: a Controlled Study Completed NCT00911521 Phase 4
15 Efficacy of Fish Oil in Lupus Patients Completed NCT00828178 Phase 4
16 Enteric-coated Mycophenolate Sodium Versus Azathioprine for the Extra-renal Lupus Manifestations Completed NCT01112215 Phase 4
17 Lupus Atherosclerosis Prevention Study Completed NCT00120887 Phase 4
18 Long-Acting Tacrolimus for the Treatment of Resistant Lupus Nephritis Completed NCT01206569 Phase 4
19 Plaquenil for Alopecia Areata, Alopecia Totalis Completed NCT00176982 Phase 4
20 Comparing the Efficacy of Tacrolimus and Mycophenolate Mofetil for the Initial Therapy of Active Lupus Nephritis Completed NCT00371319 Phase 4
21 Low-dose Combination of Mycophenolate Mofetil (MMF) and Tacrolimus (Tac) for Refractory Lupus Nephritis Completed NCT01203709 Phase 4
22 Comparison of Low Dose Versus High Dose Cyclophosphamide as Induction Therapy in the Treatment of Lupus Nephritis Completed NCT02645565 Phase 4
23 Efficacy and Safety of Belimumab in Black Race Patients With Systemic Lupus Erythematosus (SLE) Recruiting NCT01632241 Phase 4
24 A Study to Assess the Efficacy and Safety of H.P. Acthar® Gel in Subjects With Active Systemic Lupus Erythematosus (SLE) Recruiting NCT02953821 Phase 4
25 The Effect of Metformin on Reducing Lupus Flares Recruiting NCT02741960 Phase 4
26 Acthar SLE (Systemic Lupus Erythematosus) Recruiting NCT02779153 Phase 4
27 Belimumab Assessment of Safety in SLE Recruiting NCT01705977 Phase 4
28 Prophylactic Trimethoprim/Sulfamethoxazole to Prevent Severe Infections in Patients With Lupus Erythematous Recruiting NCT03042260 Phase 4
29 Safety and Immunogenicity of a Zoster Vaccine in SLE Recruiting NCT02477150 Phase 4
30 A Crossover Study to Compare RAYOS to IR Prednisone to Improve Fatigue and Morning Symptoms for SLE Recruiting NCT03098823 Phase 4
31 Evaluation of Belimumab Impact on a BLyS Activity Signature Test in the Absence of Confounding Polypharmacy Recruiting NCT02270970 Phase 4
32 ACTHAR GEL in Patients With Membranous (Class V) Lupus Nephritis Recruiting NCT01926054 Phase 4
33 ACTHar in the Treatment of Lupus Nephritis Recruiting NCT02226341 Phase 4
34 Low-dose VS High-dose IV Cyclophosphamide for Proliferative LN in Children Recruiting NCT01861561 Phase 4
35 Efficacy and Safety of Tacrolimus Versus Mycophenolate in Lupus Nephritis Recruiting NCT02630628 Phase 4
36 Acthar for the Treatment of Systemic Lupus Erythematosus in Patients With a History of Persistently Active Disease Active, not recruiting NCT01753401 Phase 4
37 Relevance of Monitoring Blood and Salivar Levels of Drugs Used in Rheumatic Autoimmune Diseases Not yet recruiting NCT03122431 Phase 4
38 Effect of Simvastatin on Endothelial Function in Premenopausal Women With Systemic Lupus Erythematosus (0733-271)(TERMINATED) Terminated NCT00739050 Phase 4
39 Trial to Study the Effects of Supplementary Omega-3 on Serum C-Reactive Protein Levels Terminated NCT00578578 Phase 4
40 A Study to Evaluate the Efficacy and Safety of Tacrolimus With Steroid in Korean Lupus Nephritis Patients Terminated NCT01316133 Phase 4
41 Levothyroxine in Pregnant SLE Patients Withdrawn NCT01276782 Phase 4
42 Doxycycline Outcomes in Lupus Erythematosus Withdrawn NCT01014260 Phase 4
43 The Efficacy and Safety of Calcitriol for the Treatment of Lupus Nephritis and Persistent Proteinuria Withdrawn NCT00508898 Phase 4
44 The Effect of Milnacipran on Fatigue and Quality of Life in Lupus Patients Withdrawn NCT01359826 Phase 4
45 Velcade for Proliferative Lupus Nephritis Withdrawn NCT01169857 Phase 4
46 Study of GL701 in Men With Systemic Lupus Erythematosus Unknown status NCT00037128 Phase 3
47 An Open Labeled Pilot Study of Atorvastatin in Systemic Lupus Erythematosus Unknown status NCT00432354 Phase 2, Phase 3
48 To Assess Prevention of Bone Loss in Women With Lupus Receiving Treatment With Glucocorticoids Unknown status NCT00053560 Phase 3
49 RING - Rituximab for Lupus Nephritis With Remission as a Goal Unknown status NCT01673295 Phase 3
50 Efficacy and Safety of Tripterygium Wilfordii in Patients With Lupus Nephritis Unknown status NCT01646736 Phase 2, Phase 3

Search NIH Clinical Center for Lupus Erythematosus

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Genetic Tests for Lupus Erythematosus

Anatomical Context for Lupus Erythematosus

MalaCards organs/tissues related to Lupus Erythematosus:

39
T Cells, Skin, B Cells, Heart, Lung, Kidney, Endothelial

Publications for Lupus Erythematosus

Articles related to Lupus Erythematosus:

(show top 50) (show all 6729)
id Title Authors Year
1
Bone Marrow Involvement in Systemic Lupus Erythematosus. ( 28525589 )
2017
2
Case of Pediatric Bullous Systemic Lupus Erythematosus Treated with Intravenous Immunoglobulin. ( 27778386 )
2017
3
The association between systemic lupus erythematosus and bipolar disorderA -A a big data analysis. ( 28525775 )
2017
4
The relevance of cluster analyses to stratify systemic lupus erythematosus: increased mortality with heavier treatment. ( 28516870 )
2017
5
Tjalma syndrome (pseudo-pseudo Meigs') as initial manifestation of juvenile-onset systemic lupus erythematosus. ( 28522234 )
2017
6
Plasma ficolin levels and risk of nephritis in Danish patients with systemic lupus erythematosus. ( 27981461 )
2017
7
Genome-Wide DNA Methylation Analysis of Chinese Patients with Systemic Lupus Erythematosus Identified Hypomethylation in Genes Related to the Type I Interferon Pathway. ( 28085900 )
2017
8
Analysis of the CD161-expressing cell quantities and CD161 expression levels in peripheral blood natural killer and T cells of systemic lupus erythematosus patients. ( 26590595 )
2017
9
Lymphadenopathy syndrome in systemic lupus erythematosus: Is it Kikuchi-Fujimoto disease? ( 27375282 )
2017
10
Pulse dose steroids in severe pulmonary arterial hypertension secondary to systemic lupus erythematosus. ( 28515936 )
2017
11
Cerebral Venous Sinus Thrombosis Presenting Feature of Systemic Lupus Erythematosus. ( 28065614 )
2017
12
Identification of long non-coding RNAs GAS5, linc0597 and lnc-DC in plasma as novel biomarkers for systemic lupus erythematosus. ( 28423570 )
2017
13
Anti-tumour necrosis factor I+-induced lupus erythematosus panniculitis. ( 28045205 )
2017
14
Dyschromatosis symmetrica hereditaria with cutaneous lupus erythematosus and hyperthyroidism. ( 28496371 )
2017
15
25-Hydroxivitamin D Serum Concentration, Not Free and Bioavailable Vitamin D, Is Associated with Disease Activity in Systemic Lupus Erythematosus Patients. ( 28085957 )
2017
16
Socioeconomic consequences of systemic lupus erythematosus. ( 28520683 )
2017
17
Associations between PTPN22 and TLR9 polymorphisms and systemic lupus erythematosus: a comprehensive meta-analysis. ( 28528372 )
2017
18
Association between circulating transforming growth factor-I^1 level and polymorphisms in systemic lupus erythematosus and rheumatoid arthritis: A meta-analysis. ( 28234629 )
2017
19
Association of IRF5 polymorphisms with increased risk for systemic lupus erythematosus in population of Crete, a southern-eastern European Greek island. ( 28185859 )
2017
20
Spatial Working Memory Impairment in Patients with Non-neuropsychiatric Systemic Lupus Erythematosus: A Blood-oxygen-level Dependent Functional Magnetic Resonance Imaging Study. ( 28089970 )
2017
21
Uveitis in childhood-onset systemic lupus erythematosus patients: a multicenter survey. ( 28070763 )
2017
22
Effects of 1,25(OH)2 D3 and vitamin D receptor on peripheral CD4(+) /CD8(+) double-positive T lymphocytes in a mouse model of systemic lupus erythematosus. ( 28063200 )
2017
23
Increased risk of hepatitis B virus reactivation in systemic lupus erythematosus patients receiving immunosuppressants: a retrospective cohort study. ( 28534427 )
2017
24
Chinese Systemic Lupus Erythematosus Treatment and Research Group Registry IX: Clinical Features and Survival of Childhood-Onset Systemic Lupus Erythematosus in China. ( 28524825 )
2017
25
A case of chilblain lupus erythematosus with lupus erythematosus/lichen planus overlap syndrome. ( 28322475 )
2017
26
Unraveling the expression of microRNA-27a* & NKG2D in peripheral blood mononuclear cells and natural killer cells of pediatric systemic lupus erythematosus patients. ( 28523761 )
2017
27
Rowell's Syndrome or subacute cutaneous lupus erythematosus? ( 27978611 )
2017
28
Medication Non-Adherence in Systemic Lupus Erythematosus: A Systematic Review. ( 28086003 )
2017
29
A Case Report of Widespread Majocchi's Granuloma in a Patient with Systemic Lupus Erythematosus. ( 28083794 )
2017
30
Elevated semaphorin5A in systemic lupus erythematosus is in association with disease activity and lupus nephritis. ( 28063160 )
2017
31
Anti-C1q Antibody is Associated with Renal and Cutaneous Manifestations in Asian Indian Patients with Systemic Lupus Erythematosus. ( 28511434 )
2017
32
Chilblain lupus erythematosus treated successfully with mycophenolate mofetil. ( 28345755 )
2017
33
Association Between TNF-I+ Promoter -308 A/G Polymorphism and Systemic Lupus Erythematosus Susceptibility: A Case-Control Study and Meta-Analysis. ( 27943420 )
2017
34
A Cutaneous Lupus Erythematosus-Like Eruption Induced by Hydroxyurea. ( 27813209 )
2017
35
Alterations of white matter structural networks in patients with non-neuropsychiatric systemic lupus erythematosus identified by probabilistic tractography and connectivity-based analyses. ( 28066709 )
2017
36
Cardiac tamponade as an initial presentation for systemic lupus erythematosus. ( 28526593 )
2017
37
Genetic advances in systemic lupus erythematosus: an update. ( 28509669 )
2017
38
Acquired hemophilia as initial presentation in a patient with Systemic Lupus Erythematosus. ( 28523993 )
2017
39
Angiotensin type 1 receptor A1166C polymorphism and systemic lupus erythematosus: correlation with cellular immunity and oxidative stress markers. ( 28530466 )
2017
40
Atypical Trigeminal Neuralgia: A Rare Neurological Manifestation of Systemic Lupus Erythematosus. ( 28077839 )
2017
41
Pneumococcal infection in patients with systemic lupus erythematosus. ( 28529115 )
2017
42
Acute necrotizing retinal vasculitis as onset of systemic lupus erythematosus: A case report. ( 28079801 )
2017
43
Gastrointestinal system involvement in systemic lupus erythematosus. ( 28523968 )
2017
44
Correlation between systemic lupus erythematosus and malignancies: a cross-sectional population-based study. ( 28091805 )
2017
45
SLAMF7 engagement restores defective effector CD8+ T cells activity in response to foreign antigens in systemic lupus erythematosus. ( 28076903 )
2017
46
Association of aortic perivascular adipose tissue density with aortic calcification in women with systemic lupus erythematosus. ( 28521185 )
2017
47
Mycobacterium avium Complex Septic Arthritis Presenting as Osteonecrosis of the Femoral Head in a Patient With Systemic Lupus Erythematosus. ( 28056158 )
2017
48
Atypical bone change of spine caused by epidural venous thrombosis in systemic lupus erythematosus with antiphospholipid syndrome. ( 28063414 )
2017
49
Multifocal Osteonecrosis in an Adolescent Patient With Systemic Lupus Erythematosus and Ankle Pain. ( 28002155 )
2017
50
Osteoporotic fractures in patients with systemic lupus erythematosus and end stage renal disease. ( 28530467 )
2017

Variations for Lupus Erythematosus

ClinVar genetic disease variations for Lupus Erythematosus:

6
id Gene Variation Type Significance SNP ID Assembly Location
1 TREX1 NM_033629.4(TREX1): c.341G> A (p.Arg114His) single nucleotide variant risk factor rs72556554 GRCh37 Chromosome 3, 48508395: 48508395

Expression for Lupus Erythematosus

Search GEO for disease gene expression data for Lupus Erythematosus.

Pathways for Lupus Erythematosus

Pathways related to Lupus Erythematosus according to GeneCards Suite gene sharing:

(show all 14)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.9 C1QA C1QB C1QC C1R C3 C4A
2
Show member pathways
13.7 C1QA C1QB C1QC C1R C3 C4A
3
Show member pathways
12.76 C1QA C1QB C1QC C3 CALR TLR5
4
Show member pathways
12.67 C3 C4A CALR CD40LG CTLA4
5
Show member pathways
12.07 C1QA C1QB C1QC C1R C3 C4A
6 12.01 C1QA C1QB C1QC C1R C3 C4A
7 11.98 C1R C3 CALR FCGR3A
8
Show member pathways
11.93 C1QA C1QB C1QC C1R C3 C4A
9
Show member pathways
11.73 C1QA C1QB C1QC C1R C3 C4A
10 11.6 CD40LG CTLA4 FCGR3A TLR5
11 11.42 SNRPB SNRPD1 SNRPD3
12 11.38 C1QA C1QB C1QC C1R C3 C4A
13 11.2 C1QA C1QB C1QC
14 10.97 C1QA C1QB C1QC C1R C3 C4A

GO Terms for Lupus Erythematosus

Cellular components related to Lupus Erythematosus according to GeneCards Suite gene sharing:

(show all 23)
id Name GO ID Score Top Affiliating Genes
1 external side of plasma membrane GO:0009897 9.89 CALR CD40LG CTLA4 FCGR3A
2 catalytic step 2 spliceosome GO:0071013 9.78 SNRPB SNRPD1 SNRPD3
3 collagen trimer GO:0005581 9.77 C1QA C1QB C1QC
4 intracellular ribonucleoprotein complex GO:0030529 9.73 SNRPB SNRPD1 SNRPD3 SSB TRIM21 TROVE2
5 U12-type spliceosomal complex GO:0005689 9.69 SNRPB SNRPD1 SNRPD3
6 U5 snRNP GO:0005682 9.63 SNRPB SNRPD1 SNRPD3
7 telomerase holoenzyme complex GO:0005697 9.61 SNRPB SNRPD3
8 U1 snRNP GO:0005685 9.61 SNRPB SNRPD1 SNRPD3
9 commitment complex GO:0000243 9.58 SNRPD1 SNRPD3
10 U7 snRNP GO:0005683 9.58 SNRPB SNRPD3
11 U2 snRNP GO:0005686 9.58 SNRPB SNRPD1 SNRPD3
12 spliceosomal tri-snRNP complex GO:0097526 9.57 SNRPD1 SNRPD3
13 pICln-Sm protein complex GO:0034715 9.56 SNRPD1 SNRPD3
14 SMN-Sm protein complex GO:0034719 9.54 SNRPB SNRPD1 SNRPD3
15 prespliceosome GO:0071010 9.52 SNRPD1 SNRPD3
16 small nuclear ribonucleoprotein complex GO:0030532 9.5 SNRPB SNRPD1 SNRPD3
17 complement component C1 complex GO:0005602 9.49 C1QA C1QB
18 methylosome GO:0034709 9.33 SNRPB SNRPD1 SNRPD3
19 U4 snRNP GO:0005687 9.13 SNRPB SNRPD1 SNRPD3
20 blood microparticle GO:0072562 9.1 C1QB C1QC C1R C3 C4A C4B
21 extracellular exosome GO:0070062 10.28 C1QA C1QB C1QC C1R C3 C4A
22 extracellular region GO:0005576 10.25 C1QA C1QB C1QC C1R C3 C4A
23 extracellular space GO:0005615 10.13 C1QA C1QB C1QC C1R C3 C4A

Biological processes related to Lupus Erythematosus according to GeneCards Suite gene sharing:

(show all 13)
id Name GO ID Score Top Affiliating Genes
1 proteolysis GO:0006508 9.98 C1QA C1QB C1QC C1R C3 C4A
2 immune response GO:0006955 9.97 C1QC C1R C3 CD40LG CTLA4 FCGR3A
3 immune system process GO:0002376 9.93 C3 C4A C4B CTLA4 PTPN22 TLR5
4 inflammatory response GO:0006954 9.91 C3 C4A C4B CD40LG TLR5
5 innate immune response GO:0045087 9.91 C1QA C1QB C1QC C1R C3 C4A
6 RNA processing GO:0006396 9.7 SNRPD1 SNRPD3 SSB
7 complement activation, classical pathway GO:0006958 9.7 C1QA C1QB C1QC C1R C3 C4A
8 spliceosomal snRNP assembly GO:0000387 9.65 SNRPB SNRPD1 SNRPD3
9 nuclear import GO:0051170 9.58 SNRPB SNRPD1 SNRPD3
10 histone mRNA metabolic process GO:0008334 9.54 SNRPB SNRPD3 SSB
11 positive regulation of apoptotic cell clearance GO:2000427 9.5 C3 C4A C4B
12 regulation of complement activation GO:0030449 9.5 C1QA C1QB C1QC C1R C3 C4A
13 complement activation GO:0006956 9.17 C1QA C1QB C1QC C1R C3 C4A

Molecular functions related to Lupus Erythematosus according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 RNA binding GO:0003723 9.92 CALR SNRPB SNRPD1 SNRPD3 SSB TRIM21
2 telomerase RNA binding GO:0070034 9.43 SNRPB SNRPD3
3 complement component C1q binding GO:0001849 9.4 C4A CALR
4 U1 snRNP binding GO:1990446 9.37 SNRPD1 SNRPD3
5 endopeptidase inhibitor activity GO:0004866 9.33 C3 C4A C4B
6 histone pre-mRNA DCP binding GO:0071208 9.26 SNRPB SNRPD3
7 serine-type endopeptidase activity GO:0004252 9.17 C1QA C1QB C1QC C1R C3 C4A
8 U2 snRNA binding GO:0030620 9.13 SNRPB SNRPD3 TROVE2

Sources for Lupus Erythematosus

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....